Skip to content
Cinoxacin
Cinobac (cinoxacin) is a small molecule pharmaceutical. Cinoxacin was first approved as Cinobac on 1982-01-01. It is used to treat escherichia coli infections, klebsiella infections, proteus infections, and urinary tract infections in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cinoxacin
Tradename
Company
Number
Date
Products
CINOBACEli LillyN-018067 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
escherichia coli infectionsEFO_1001318D004927B96.20
klebsiella infectionsEFO_1001353D007710—
proteus infectionsEFO_1001130D011512—
urinary tract infectionsEFO_0003103D014552N39.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01M: Quinolone antibacterials
— J01MB: Other quinolones in atc
— J01MB06: Cinoxacin
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
OnychomycosisD014009B35.1—11215
Seborrheic dermatitisD012628L21———1—1
Foot dermatosesD005533———1—1
DermatomycosesD003881———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tinea pedisD014008EFO_0007512B35.3——1—12
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01————1
Hematologic neoplasmsD0193371————1
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.01————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_00003401————1
Hodgkin diseaseD006689C811————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tinea capitisD014006B35.0————11
Vulvar neoplasmsD014846C51————11
InfectionsD007239EFO_0000544————11
Nail diseasesD009260HP_0001597L60————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCINOXACIN
INNcinoxacin
Description
Cinoxacin is a member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections. It has a role as an antibacterial drug and an antiinfective agent. It is a member of cinnolines, an oxo carboxylic acid and an oxacycle.
Classification
Small molecule
Drug classantibacterials (quinolone derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCn1nc(C(=O)O)c(=O)c2cc3c(cc21)OCO3
Identifiers
PDB—
CAS-ID28657-80-9
RxCUI2550
ChEMBL IDCHEMBL1208
ChEBI ID3716
PubChem CID2762
DrugBankDB00827
UNII IDLMK22VUH23 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
582 adverse events reported
View more details